{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:36:39Z","timestamp":1783528599030,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Propranolol, a non-selective \u03b2-adrenergic receptor blocker, is the first FDA-approved orphan drug for the treatment of infantile hemangioma (IH). While it has demonstrated substantial therapeutic benefits, the safety profile of propranolol in infants remains insufficiently characterized, particularly in real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective pharmacovigilance analysis of FAERS reports from Q1 2015 to Q4 2024 was conducted, applying four signal detection algorithms (ROR, PRR, BCPNN, MGPS) to identify disproportional AE signals related to propranolol in IH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1615 AE reports were included. Signal detection identified events across 20 System Organ Classes (SOCs), with vascular, psychiatric, and metabolism and nutrition disorders being most prominent. At the Preferred Term (PT) level, the most frequently reported AEs were sleep disorder (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009149, ROR\u2009=\u200932.67), peripheral coldness (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200987, ROR\u2009=\u2009108.73), and hypoglycaemia (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200962, ROR\u2009=\u200922.95), which were pharmacologically plausible and clinically relevant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study identified safety signals associated with propranolol in infants with IH, highlighting risks across organ systems. These findings support the need for vigilant monitoring, individualized risk assessment, and refinement of labeling recommendations to optimize safety in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04331-4","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:36:32Z","timestamp":1775061392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Orphan drug propranolol for infantile hemangioma: ten-year real-world safety data from the FAERS database"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8501-454X","authenticated-orcid":false,"given":"Xuanjia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"4331_CR1","doi-asserted-by":"crossref","unstructured":"George A, Mani V, Noufal A. Update on the classification of hemangioma. J Oral Maxillofac Pathol. 2014;18(Suppl 1):S117\u201320.","DOI":"10.4103\/0973-029X.141321"},{"issue":"6","key":"4331_CR2","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jaad.2021.08.019","volume":"85","author":"AI Rodr\u00edguez Bandera","year":"2021","unstructured":"Rodr\u00edguez Bandera AI, et al. Infantile hemangioma. Part, 1: epidemiology, pathogenesis, clinical presentation and assessment. J Am Acad Dermatol. 2021;85(6):1379\u201392.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4331_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1573396316666200508100038","volume":"17","author":"AKC Leung","year":"2021","unstructured":"Leung AKC, et al. Infantile hemangioma: an updated review. Curr Pediatr Rev. 2021;17(1):55\u201369.","journal-title":"Curr Pediatr Rev"},{"issue":"10089","key":"4331_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0140-6736(16)00645-0","volume":"390","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2017","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85\u201394.","journal-title":"Lancet"},{"key":"4331_CR5","doi-asserted-by":"crossref","unstructured":"Krowchuk DP, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1).","DOI":"10.1542\/peds.2018-3475"},{"issue":"6","key":"4331_CR6","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.jaad.2021.08.020","volume":"85","author":"DF Sebaratnam","year":"2021","unstructured":"Sebaratnam DF, et al. Infantile hemangioma. Part, 2: management. J Am Acad Dermatol. 2021;85(6):1395\u2013404.","journal-title":"J Am Acad Dermatol"},{"issue":"1s","key":"4331_CR7","doi-asserted-by":"publisher","first-page":"101313","DOI":"10.1016\/j.jormas.2022.10.012","volume":"124","author":"P Tiwari","year":"2023","unstructured":"Tiwari P, Bera RN, Pandey V. Bleomycin-triamcinolone sclerotherapy in the management of propranolol resistant infantile hemangioma of the maxillofacial region: a single arm prospective evaluation of clinical outcome and doppler ultrasound parameters. J Stomatol Oral Maxillofac Surg. 2023;124(1s):101313.","journal-title":"J Stomatol Oral Maxillofac Surg"},{"issue":"24","key":"4331_CR8","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649\u201351.","journal-title":"N Engl J Med"},{"issue":"4","key":"4331_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ijporl.2010.01.001","volume":"74","author":"AP Zimmermann","year":"2010","unstructured":"Zimmermann AP, et al. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol. 2010;74(4):338\u201342.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"8","key":"4331_CR10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735\u201346.","journal-title":"N Engl J Med"},{"key":"4331_CR11","doi-asserted-by":"crossref","unstructured":"L\u00e9aute-Labr\u00e8ze C, et al. Safety of Oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics. 2016;138(4).","DOI":"10.1542\/peds.2016-0353"},{"issue":"2","key":"4331_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/pde.14537","volume":"38","author":"E Pope","year":"2021","unstructured":"Pope E. Commentary: Beta-blockers and sleep problems. Pediatr Dermatol. 2021;38(2):378\u201379.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"4331_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00431-022-04674-7","volume":"182","author":"MM Hermans","year":"2023","unstructured":"Hermans MM, et al. Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. Eur J Pediatr. 2023;182(2):757\u201367.","journal-title":"Eur J Pediatr"},{"key":"4331_CR14","doi-asserted-by":"crossref","unstructured":"Opri F, et al. Assessing response rates and sleep disorder prevalence: insights from a propranolol treatment study for infantile haemangiomas. Vol. 11 (9). Children (Basel); 2024.","DOI":"10.3390\/children11091086"},{"issue":"10","key":"4331_CR15","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.16601","volume":"54","author":"TA Wichelmann","year":"2021","unstructured":"Wichelmann TA, Abdulmujeeb S, Ehrenpreis ED. Bevacizumab and gastrointestinal perforations: a review from the FDA adverse event reporting system (FAERS) database. Aliment. Pharmacol. Ther. 2021;54(10):1290\u201397.","journal-title":"Aliment. Pharmacol. Ther"},{"issue":"4","key":"4331_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/8755122520928495","volume":"36","author":"MA Veronin","year":"2020","unstructured":"Veronin MA, Schumaker RP, Dixit R. The irony of MedWatch and the FAERS database: an assessment of data input errors and potential consequences. J Pharm Technol. 2020;36(4):164\u201367.","journal-title":"J Pharm Technol"},{"key":"4331_CR17","doi-asserted-by":"publisher","first-page":"1225919","DOI":"10.3389\/fphar.2023.1225919","volume":"14","author":"S Su","year":"2023","unstructured":"Su S, et al. Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS). Front Pharmacol. 2023;14:1225919.","journal-title":"Front Pharmacol"},{"key":"4331_CR18","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","volume":"15","author":"F Zou","year":"2024","unstructured":"Zou F, et al. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol. 2024;15:1338902.","journal-title":"Front Pharmacol"},{"key":"4331_CR19","first-page":"37","volume":"2014","author":"M Jiang","year":"2014","unstructured":"Jiang M, et al. Extracting and standardizing medication information in clinical text - the MedEx-UIMA system. AMIA Jt Summits Transl Sci Proc. 2014;2014:37\u201342.","journal-title":"AMIA Jt Summits Transl Sci Proc"},{"issue":"8","key":"4331_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"4331_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u201386.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"4331_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur. J. Clin. Pharmacol"},{"issue":"2","key":"4331_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/14740338.2024.2438751","volume":"25","author":"M Chen","year":"2026","unstructured":"Chen M, et al. Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database. Expert Opin Drug Saf. 2026;25(2):401\u201309.","journal-title":"Expert Opin Drug Saf"},{"key":"4331_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, et al. Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. J Affect Disord. 2024;346:223\u201329.","journal-title":"J Affect Disord"},{"issue":"6","key":"4331_CR25","first-page":"7","volume":"22","author":"Y Chen","year":"2008","unstructured":"Chen Y, et al. Comparison of sensitivity and timing of early signal detection of four frequently used signal detection methods: an empirical study based on the US FDA Adverse Event Reporting System database. Int J Multiling Pharm Med. 2008;22(6):7.","journal-title":"Int J Multiling Pharm Med"},{"key":"4331_CR26","first-page":"3031","volume-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases","author":"K Nomura","year":"2015","unstructured":"Nomura K, et al. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Vol. 9. Drug Des Devel Ther; 2015. p. 3031\u201341."},{"key":"4331_CR27","doi-asserted-by":"publisher","first-page":"621691","DOI":"10.3389\/fphar.2021.621691","volume":"12","author":"AR Eugene","year":"2021","unstructured":"Eugene AR, et al. Head-to-Head Comparison of sedation and somnolence among 37 antipsychotics in schizophrenia, bipolar disorder, Major depression, autism spectrum disorders, delirium, and repurposed in COVID-19, infectious diseases, and oncology from the FAERS, 2004-2020. Front Pharmacol. 2021;12:621691.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4331_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40360-024-00772-4","volume":"25","author":"L Jin","year":"2024","unstructured":"Jin L, et al. Safety assessment of asenapine in the FAERS database: real adverse event analysis and discussion on neurological and psychiatric side effects. BMC Pharmacol Toxicol. 2024;25(1):49.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"4331_CR29","doi-asserted-by":"publisher","first-page":"10709","DOI":"10.1038\/s41598-021-90108-7","volume":"11","author":"B Wu","year":"2021","unstructured":"Wu B, et al. A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data. Sci Rep. 2021;11(1):10709.","journal-title":"Sci Rep"},{"key":"4331_CR30","doi-asserted-by":"publisher","first-page":"1388138","DOI":"10.3389\/fphar.2024.1388138","volume":"15","author":"N Tian","year":"2024","unstructured":"Tian N, et al. Safety assessment of tranexamic acid: real-world adverse event analysis from the FAERS database. Front Pharmacol. 2024;15:1388138.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4331_CR31","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1038\/s41598-018-22787-8","volume":"8","author":"Y Ji","year":"2018","unstructured":"Ji Y, et al. Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. Sci Rep. 2018;8(1):4264.","journal-title":"Sci Rep"},{"issue":"8","key":"4331_CR32","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1007\/s00431-021-04147-3","volume":"180","author":"M Theiler","year":"2021","unstructured":"Theiler M, et al. Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study. Eur J Pediatr. 2021;180(8):2655\u201368.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"4331_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bjd.13379","volume":"172","author":"A Langley","year":"2015","unstructured":"Langley A, Pope E. Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas. Br J Dermatol. 2015;172(1):13\u201323.","journal-title":"Br J Dermatol"},{"key":"4331_CR34","unstructured":"Malinowska B, et al. [Beta-adrenergic receptors in the cardiovascular system. The participation of propranolol insensitive beta-adrenoceptors in the regulation of the cardiovascular system]. Kardiol Pol. 2005;63(4 Suppl 2):S399\u2013408."},{"issue":"6","key":"4331_CR35","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1161\/01.CIR.40.6.855","volume":"40","author":"WD Berkowitz","year":"1969","unstructured":"Berkowitz WD, et al. The effects of propranolol on cardiac conduction. Circulation. 1969;40(6):855\u201362.","journal-title":"Circulation"},{"issue":"2","key":"4331_CR36","first-page":"124","volume":"22","author":"BW Burkey","year":"2017","unstructured":"Burkey BW, Jacobs JA, Aziz H. Temperature instability in an infant treated with propranolol for infantile hemangioma. J Pediatr Pharmacol Ther. 2017;22(2):124\u201327.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"4331_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0091-6749(71)90009-1","volume":"48","author":"MH Grieco","year":"1971","unstructured":"Grieco MH, R.N P Jr. Mechanism of bronchoconstriction due to beta adrenergic blockade. Studies with practolol, propranolol, and atropine. J. Allergy Clin. Immunol. 1971;48(3):143\u201352.","journal-title":"J. Allergy Clin. Immunol"},{"issue":"1","key":"4331_CR38","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/s41598-017-01321-2","volume":"7","author":"Y Ji","year":"2017","unstructured":"Ji Y, et al. Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study. Sci Rep. 2017;7(1):1503.","journal-title":"Sci Rep"},{"issue":"5","key":"4331_CR39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s12519-019-00335-2","volume":"16","author":"EMS Xerfan","year":"2020","unstructured":"Xerfan EMS, et al. Sleep disturbances as an adverse effect of propranolol use in children with infantile hemangioma. World J Pediatr. 2020;16(5):537\u201338.","journal-title":"World J Pediatr"},{"issue":"1","key":"4331_CR40","doi-asserted-by":"publisher","first-page":"7493","DOI":"10.1038\/s41598-023-34401-7","volume":"13","author":"SA Jami","year":"2023","unstructured":"Jami SA, et al. Functional and phosphoproteomic analysis of \u03b2-adrenergic receptor signaling at excitatory synapses in the CA1 region of the ventral hippocampus. Sci Rep. 2023;13(1):7493.","journal-title":"Sci Rep"},{"issue":"7","key":"4331_CR41","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/archdermatol.2010.158","volume":"146","author":"KE Holland","year":"2010","unstructured":"Holland KE, et al. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol. 2010;146(7):775\u201378.","journal-title":"Arch Dermatol"},{"key":"4331_CR42","doi-asserted-by":"crossref","unstructured":"Morimoto A, et al. Severe hypoglycemia in propranolol treatment for infantile hemangiomas. Pediatr Int. 2022;64(1):e15278.","DOI":"10.1111\/ped.15278"},{"issue":"1","key":"4331_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1542\/peds.2012-1691","volume":"131","author":"BA Drolet","year":"2013","unstructured":"Drolet BA, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128\u201340.","journal-title":"Pediatrics"},{"issue":"9","key":"4331_CR44","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJM197508282930902","volume":"293","author":"RR Miller","year":"1975","unstructured":"Miller RR, et al. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med. 1975;293(9):416\u201318.","journal-title":"N Engl J Med"},{"issue":"2","key":"4331_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1185\/03007998009112032","volume":"7","author":"JA Thorpe","year":"1980","unstructured":"Thorpe JA. Effect of propranolol on the lower oesophageal sphincter in man. Curr Med Res Opin. 1980;7(2):91\u201395.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"4331_CR46","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/00034894221089758","volume":"132","author":"T Chen","year":"2023","unstructured":"Chen T, et al. Should propranolol remain the Gold standard for treatment of infantile hemangioma? A systematic review and meta-analysis of propranolol versus atenolol. Ann Otol Rhinol Laryngol. 2023;132(3):332\u201340.","journal-title":"Ann Otol Rhinol Laryngol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04331-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04331-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04331-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:21:05Z","timestamp":1781644865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04331-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4331"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04331-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is based on publicly available data from the FDA Adverse Event Reporting System (FAERS) and does not involve human participants or animal subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}